These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 27801993)
1. Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancer. Okabe M; Toh U; Iwakuma N; Saku S; Akashi M; Kimitsuki Y; Seki N; Kawahara A; Ogo E; Itoh K; Akagi Y Cancer Sci; 2017 Jan; 108(1):81-90. PubMed ID: 27801993 [TBL] [Abstract][Full Text] [Related]
2. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma. Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334 [TBL] [Abstract][Full Text] [Related]
3. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145 [TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578 [TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma. Liu P; Xiao Q; Zhou B; Dai Z; Kang Y World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313 [TBL] [Abstract][Full Text] [Related]
8. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649 [TBL] [Abstract][Full Text] [Related]
9. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868 [TBL] [Abstract][Full Text] [Related]
10. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062 [TBL] [Abstract][Full Text] [Related]
11. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. Silva-Figueroa A; Villalobos P; Williams MD; Bassett RL; Clarke CN; Lee JE; Busaidy NL; Perrier ND Surgery; 2018 Nov; 164(5):960-964. PubMed ID: 30033186 [TBL] [Abstract][Full Text] [Related]
12. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Duchnowska R; Pęksa R; Radecka B; Mandat T; Trojanowski T; Jarosz B; Czartoryska-Arłukowicz B; Olszewski WP; Och W; Kalinka-Warzocha E; Kozłowski W; Kowalczyk A; Loi S; Biernat W; Jassem J; Breast Cancer Res; 2016 Apr; 18(1):43. PubMed ID: 27117582 [TBL] [Abstract][Full Text] [Related]
13. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Berghoff AS; Kiesel B; Widhalm G; Rajky O; Ricken G; Wöhrer A; Dieckmann K; Filipits M; Brandstetter A; Weller M; Kurscheid S; Hegi ME; Zielinski CC; Marosi C; Hainfellner JA; Preusser M; Wick W Neuro Oncol; 2015 Aug; 17(8):1064-75. PubMed ID: 25355681 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor PD-L1 expression combined with CD8 Wang Q; Lou W; Di W; Wu X Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888 [TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer. Hou Y; Nitta H; Wei L; Banks PM; Lustberg M; Wesolowski R; Ramaswamy B; Parwani AV; Li Z Breast J; 2018 Nov; 24(6):911-919. PubMed ID: 30230111 [TBL] [Abstract][Full Text] [Related]
17. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. Hirakata T; Fujii T; Kurozumi S; Katayama A; Honda C; Yanai K; Tokuda S; Nakazawa Y; Obayashi S; Yajima R; Kaira K; Oyama T; Shirabe K Breast Cancer Res Treat; 2020 Jun; 181(2):331-338. PubMed ID: 32253685 [TBL] [Abstract][Full Text] [Related]
18. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma. Hu C; Tian S; Lin L; Zhang J; Ding H Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy. Han M; Li J; Wu S; Wu C; Yu Y; Liu Y Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303 [TBL] [Abstract][Full Text] [Related]
20. Functional CD3 Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]